Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors

Microbes and Infection

Volumn 12, Issue 14-15, 2010, Pages 1170-1177

  Tanuma, Junko ^a,c   Hachiya, Atsuko ^a   Ishigaki, Kyoko ^a   Gatanaga, Hiroyuki ^a   Minh Lien, Trinh Thi ^b   Hien, Nguyen Duc ^b   Van Kinh, Nguyen ^b   Kaku, Mitsuo ^c   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b National Hospital of Tropical Diseases   (Viet Nam)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A371V; CRF01_AE; Drug resistance; G335D; Reverse transcriptase

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; THYMIDINE; ZIDOVUDINE;

ADULT; ARTICLE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS RESISTANCE;

ADULT; AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE; VIETNAM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78649898894     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2010.08.003     Document Type: Article

References (45)

1. Gilks C.F., Crowley S., Ekpini R., Gove S., Perriens J., Souteyrand Y., Sutherland D., Vitoria M., Guerma T., De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368:505-510.
2. Ministry of Health of Viet Nam Decision by the Minister of Health on the Issuance of the Guidelines for HIV/AIDS Diagnosis and Treatment: Guidelines for HIV/AIDS Diagnosis and Treatment 2005, Health Publishing House, No: 06/2005QD-BYT.
3. UNAIDS/WHO AIDS epidemic update ASIA regional summary 2007 Available from:. http://data.unaids.org/pub/Report/2008/jc1527_epibriefs_asia_en.pdf.
4. UNAIDS/WHO Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections Available from:. http://apps.who.int/GlobalAtlas/predefinedReports/EFS2008/index.asp.
5. Ministry of Health of Viet Nam The third country report on following up the implementation to the declaration of commitment on HIV and AIDS Available from:. http://data.unaids.org/pub/Report/2008/viet_nam_2008_country_progress_report_en.pdf.
6. Bennett D.E., Myatt M., Bertagnolio S., Sutherland D., Gilks C.F. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther. 2008, 13:25-36.
7. Brehm J.H., Koontz D., Meteer J.D., Pathak V., Sluis-Cremer N., Mellors J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J. Virol. 2007, 81:7852-7859.
8. Delviks-Frankenberry K.A., Nikolenko G.N., Barr R., Pathak V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J. Virol. 2007, 81:6837-6845.
9. Delviks-Frankenberry K.A., Nikolenko G.N., Boyer P.L., Huges S.H., Coffin J.M., Jere A., Pathak V.K. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. USA 2008, 105:10943-10948.
10. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 2008, 82:3261-3270.
11. Nikolenko G.N., Delviks-Frankenberry K.A., Palmer S., Maldarelli F., Fivash M.J., Coffin J.M., Pathak V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. Proc. Natl. Acad. Sci. USA 2007, 104:317-322.
12. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 2007, 4. e335.
13. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., Harrigan P.R., Götte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J. Biol. Chem. 2008, 283:22222-22232.
14. Zelina S., Sheen C.W., Radzio J., Mellors J.W., Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob. Agents Chemother. 2008, 52:157-163.
15. Brehm J.H., Mellors J.W., Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008, 47:14020-14027.
16. Delviks-Frankenberry K.A., Nikolenko G.N., Maldarelli F., Hase S., Takebe Y., Pathak V.K. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine. J. Virol. 2009, 83:8502-8513.
17. Kemp S.D., Shi C., Bloor S., Harrigan P.R., Mellors J.W., Larder B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J. Virol. 1998, 72:5093-5098.
18. Ntemgwa M., Wainberg M.A., Oliveira M., Moisi D., Lalonde R., Micheli V., Brenner B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 2007, 51:3861-3869.
19. Santos A.F., Lengruber R.B., Soares E.A., Jere A., Sprinz E., Martinez A.M., Silveira J., Sion F.S., Pathak V.K., Soares M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. PLoS ONE 2008, 3. e1781.
20. Hachiya A., Shimane K., Sarafianose S.G., Kodama E.N., Sakagami Y., Negishi F., Koizumi H., Gatanaga H., Matsuoka M., Takiguchi M., Oka S. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. Antiviral. Res. 2009, 82:115-121.
21. Buonaguro L., Tornesello M.L., Buonaguro F.M. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 2007, 81:10209-10219.
22. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr. Opin. Infect. Dis. 2006, 19:594-606.
23. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Soares M.A., Snoeck J., Pillay C., Rudich H., Rodrigues R., Holguin A., Ariyoshi K., Bouzas M.B., Cahn P., Sugiura W., Soriano V., Brigido L.F., Grossman Z., Morris L., Vandamme A.M., Tanuri A., Phanuphak P., Weber J.N., Pillay D., Harrigan P.R., Camacho R., Schapiro J.M., Shafer R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005, 2. e112.
24. Snoeck J., Kantor R., Shafer R.W., Van Laethem K., Deforche K., Carvalho A.P., Wynhoven B., Soares M.A., Cane P., Clarke J., Pillay C., Sirivichayakul S., Ariyoshi K., Holguin A., Rudich H., Rodrigues R., Bouzas M.B., Brun-Vézinet F., Reid C., Cahn P., Brigido L.F., Grossman Z., Soriano V., Sugiura W., Phanuphak P., Morris L., Weber J., Pillay D., Tanuri A., Harrigan R.P., Camacho R., Schapiro J.M., Katzenstein D., Vandamme A.M. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob. Agents Chemother. 2006, 50:694-701.
25. Caride E., Brindeiro R., Hertogs K., Larder B., Dehertogh P., Machado E., de Sá C.A., Eyer-Silva W.A., Sion F.S., Passioni L.F., Menezes J.A., Calazans A.R., Tanuri A. Drug-resistant reverse transcriptase genotyping and phenotyping of B and Non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000, 275:107-115.
26. Montes B., Vergne L., Peeters M., Reynes J., Delaporte E., Segondy M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J. Acquir. Immune. Defic. Syndr. 2004, 35:329-336.
27. Novitsky V., Wester C.W., DeGruttola V., Bussmann H., Gaseitsiwe S., Thomas A., Moyo S., Musonda R., Van Widenfelt E., Marlink R.G., Essex M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV Type 1C-infected adults treated with ZDV/ddI-Containing HAART in Southern Africa. AIDS Res. Hum. Retrovir. 2007, 23:868-878.
28. Ariyoshi K., Matsuda M., Miura H., Tateishi S., Yamada K., Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune. Defic. Syndr. 2003, 33:336-342.
29. Hsu L.Y., Subramaniam R., Bacheler L., Paton N.I. Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore. J. Acquir. Immune. Defic. Syndr. 2005, 38:5-13.
30. Yam W.C., Chen J.H., Wong K.H., Chan K., Cheng V.C., Lam H.Y., Lee S.S., Zheng B.J., Yuen K.Y. Clinical utility of genotyping resistance test on determining the mutation patterns in HIV-1 CRF01_AE and subtype B patients receiving antiretroviral therapy in Hong Kong. J. Clin. Virol. 2006, 35:454-457.
31. Sukasem C., Churdboonchart V., Sukeepaisarncharoen W., Piroj W., Inwisai T., Tiensuwan M., Chantratita W. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int. J. Antimicrob. Agents 2008, 31:277-281.
32. Nguyen T.H.L., Recordon-Pinson P., Pham V.H., Uyen N.T., Lien T.T., Tien H.T., Garrigue I., Schrive M.H., Pellegrin I., Lafon M.E., Aboulker J.P., Barré-Sinoussi F., Fleury H.J. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res. Hum. Retrovir. 2003, 19:925-928.
33. Tran T.T.H., Maljkovic I., Swartling S., Phung D.C., Chiodi F., Leitner T. HIV-1 CRF01_AE in intravenous drug users in Hanoi, Vietnam. AIDS Res. Hum. Retrovir. 2004, 20:341-345.
34. Ishizaki A., Nguyen H.C., Thuc P.V., Nguyen V.T., Saijoh K., Kageyama S., Ishigaki K., Tanuma J., Oka S., Ichimura H. Profile of HIV Type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV type 1-infected individuals in Hai Phong, Viet Nam. AIDS Res. Hum. Retrovir. 2009, 25:175-182.
35. + cell clone 1-10 (MAGIC-5). Antimicrob. Agents Chemother. 2001, 45:495-501.
36. Johnson V.A., Brun-Vézinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 2009, 17:138-145.
37. Hu Z., Giguel F., Hatano H., Reid P., Lu J., Kuritzkes D.R. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J. Virol. 2006, 80:7020-7027.
38. Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., Kuritzkes D.R., Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007, 21:215-223.
39. Bennett D.E., Camacho R.J., Otelea D., Kuritzkes D.R., Fleury H., Kiuchi M., Heneine W., Kantor R., Jordan M.R., Schapiro J.M., Vandamme A.M., Sandstrom P., Boucher C.A., van de Vijver D., Rhee S.Y., Liu T.F., Pillay D., Shafer R.W. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009, 4. e4724.
40. Saeng-aroon S., Tsuchiya N., Auwanit W., Ayuthaya P.I., Pathipvanich P., Sawanpanyalert P., Rojanawiwat A., Kannagi M., Ariyoshi K., Sugiura W. Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: follow-up study from the Lampang cohort. Antivir. Res. 2010, 87:22-29.
41. Gupta S., Fransen S., Paxinos E., Huang W., Dua R., Stawiski E., Petropoulos C., Parkin N. Infrequent occurrence of mutations in the C-terminal region of reverse transcriptase modulates susceptibility to RT inhibitors. Antivir. Ther. 2006, 11:S143.
42. Poveda E., de Mendoza C., Pattery T., González M., Villacian J., Soriano V. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008, 22:2395-2398.
43. Winters B., Van Craenenbroeck E., Van der Borght K., Lecocq P., Villacian J., Bacheler L. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J. Virol. Methods 2009, 162:101-108.
44. Wang B., Lau K.A., Ong L.Y., Shah M., Steain M.C., Foley B., Dwyer D.E., Chew C.B., Kamarulzaman A., Ng K.P., Saksena N.K. Complex patterns of the HIV-1 epidemic in Kuala Lumpur, Malaysia: evidence for expansion of circulating recombinant form CRF33_01B and detection of multiple other recombinants. Virology 2007, 367:288-297.
45. Tee K.K., Pon C.K., Kamarulzaman A., Ng K.P. Emergence of HIV-1 CRF01_AE/B unique recombinant forms in Kuala Lumpur, Malaysia. AIDS 2005, 19:119-126.